Compounds > 3,4-dihydroxyphenylacetic acid

3,4-dihydroxyphenylacetic acid and chlorisondamine

3,4-dihydroxyphenylacetic acid has been researched along with chlorisondamine in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andén, NE; Grabowska-Andén, M; Klaesson, L1
Abin-Carriquiry, JA; Costa, G; Dajas, F1

Other Studies

2 other study(ies) available for 3,4-dihydroxyphenylacetic acid and chlorisondamine

ArticleYear
Stimulation of the synthesis of catecholamines in a sympathetic ganglion via cholinergic and non-cholinergic mechanisms.
    Naunyn-Schmiedeberg's archives of pharmacology, 1986, Volume: 333, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Atropine; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Catecholamines; Chlorisondamine; Dopamine; Electric Stimulation; Ganglia, Sympathetic; Male; Methoxyhydroxyphenylglycol; Norepinephrine; Rats; Rats, Inbred Strains; Receptors, Cholinergic

1986
Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra.
    Brain research, 2001, Jan-12, Volume: 888, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chlorisondamine; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Injections, Subcutaneous; Male; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra

2001